MoonLake Immunotherapeutics (MLTX): R&D Expense
$202.86M
Year ended 2025-12-31
$221.38M
Trailing 12 months to 2026-06-30
+69.0%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $202.86M | +79.9% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $112.77M | +254.6% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $31.80M | -24.4% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $42.05M | n/a | 2025-02-26, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $202.86M | +79.9% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $137.92M | +54.7% |
| Bicara Therapeutics Inc. (BCAX) | 2024-12-31 | $63.60M | +107.8% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $77.05M | +0.8% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $672.7K | -50.6% |
| Alumis Inc. (ALMS) | 2025-12-31 | $386.00M | +45.4% |
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $109.82M | -3.7% |
| Nkarta, Inc. (NKTX) | 2025-12-31 | $90.43M | -6.5% |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | $121.20M | +65.8% |
Compare MLTX, STOK, BCAX, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗